Prospects for 2015, page-7

A timeline for the fully implantable to be trialed using the existing 13 sites in EU is what will really make it fly.
Commercialisation in EU of the fully implantable could be underway in 2016. That would pave the way for the fully implantable to replace the existing C-Pulse at the end of the US pivotal trial. The fully implantable will likely be over 90% redundant to the existing C-Pulse so it should be a relatively small step to get FDA approval to do the switch.